Good day, everyone, and welcome to the Assembly Biosciences Annual Meeting. Now, I'll turn the call over to your host, Chairman Anthony Altig. Please go ahead, Anthony. Good morning. I'm Anthony Altig, Chairman of the Board of Assembly Biosciences and a candidate for re-election as a director. Welcome to our 2026 annual meeting of stockholders. We're holding this meeting through a virtual-only online platform. Before we start with the formal business of the meeting, I would like to take a minute to recognize and thank my predecessor as Chairman, Bill Ringo, for all his contributions to the Board and to Assembly Bio. Bill joined the Board in 2014 and served as Chairman starting in 2015. Bill led the Board as the Company underwent many changes, including the Company's scope beyond strictly Hepatitis B. Bill has elected not to run for re-election and to step down from the Board. We're thankful to Bill for all his many contributions to the Company. With that said, thank you all for taking the time to join us. The meeting is now called to order. Please note that in addition to me, our CEO and President, Jason Okazaki, is present at the meeting, and we encourage all our current directors running for re-election to the board to attend the meeting as well. Present at this meeting is John Gunderson, our Vice President, General Counsel, and Corporate Secretary, who is serving as Inspector of Election for today's meeting. As described in the notice of the meeting and the proxy statement provided to stockholders, the record date for voting at this meeting was the close of business on April 10, 2026. While the meeting is virtual only, stockholders will be able to submit questions online during the meeting by using the Q&A function in the virtual meeting portal. Note that we will only address questions directly related to the business being conducted at the meeting that have not already been addressed in another location, such as the proxy statement. As Chairman of the Board, I will chair the meeting, and John will serve as Secretary of the Meeting and Inspector of Elections. Prior to the meeting, John signed an oath to act as Inspector of Election, which will be filed with the minutes of the meeting. John, will you please report on the meeting's attendance and the presence of a quorum? Thanks, Tony. As of the April 10th record date for the meeting, there were 15,892,608 shares of common stock outstanding and entitled to vote at this meeting. According to an affidavit of distribution from Broadridge Financial Solutions, on April 22nd, 2026, Broadridge commenced the mailing of a notice of annual meeting of stockholders or notice of internet availability of proxy materials to all stockholders of record as of the record date. The affidavit is available if any stockholder wants to examine it, and it will be filed with the minutes of this meeting. A preliminary count of the shares represented by proxy at this meeting indicates that approximately 78% of the shares of common stock outstanding as of the record date and entitled to vote are present at the meeting by proxy. A quorum is present at the meeting. Thank you. The meeting is duly conveyed and open for business. It's now 8:03 A.M. Pacific Time. Polls will be open for voting until they are closed later in the meeting. Should any stockholder wish to vote online at this time or change a previously submitted vote, now is the time to vote through the virtual meeting portal. If you've already delivered your proxy and you do not wish to change your vote, your vote will be recorded, and you do not need to vote online at this time. Let's move forward to the formal business of the meeting. As described in the agenda, which has been posted in the meeting portal along with the rules of conduct for the meeting, we are considering five proposals at this meeting. Each of these items was described in the proxy materials previously made available to all stockholders of record. After the presentation of the proposals, we'll take questions. Questions should be limited to the proposals being considered. The first item of business is to elect nine directors to serve on our Board of Directors until the annual meeting of stockholders in 2027 and until their successors are duly elected and qualified. The nominees are Anthony Altig, Tomas Cihlar, Gina Consylman, Rob Cook, Michael Houghton, Lisa Johnson-Pratt, Sue Mahony, John McHutchison, and Jason Okazaki. The board recommends a vote for each of these years' nominees. The second item of business is the approval on a non-binding advisory basis of our named executive officers' compensation as disclosed in the proxy statement, as required by the SEC's compensation disclosure rules. The board recommends a vote for the approval of the named executive officers' compensation. The third item to be considered is the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the 2026 fiscal year by the board's audit committee. We have with us on the line today Sarah McDonald, a partner involved with the Assembly Bio audit performed by Ernst & Young LLP, who will respond to any appropriate questions after the presentation of proposals. The board recommends a vote for the ratification of Ernst & Young LLP as the company's independent registered public accounting firm. The fourth item for consideration is an amendment to the amended and restated Assembly Biosciences, Inc. 2018 incentive plan to increase the number of shares reserved for issuance under the plan by 1.2 million shares. The entire 2018 plan, including the proposed amendment, has been included in the proxy statement that was filed with the SEC and made available to stockholders of record. The board recommends a vote for the amendment to the 2018 stock incentive plan. The fifth and final item for consideration is to approve an amendment to the second amended and restated Assembly Biosciences, Inc. 2018 employee stock purchase plan to increase the number of shares reserved to 515,000 shares. The entire ESPP, including the proposed amendment, has been included in the proxy statement. The board recommends a vote for the amendment to the ESPP. Questions? No questions. As there have been no questions submitted, let's turn to the next item on the agenda, voting. For any stockholders present who have not yet voted, the polls will close momentarily. If you've already submitted a vote, you will only need to vote now if you want to change your vote. Any votes submitted during the meeting will be reflected in the final results, which will be reported after the meeting. It is now 8:07 A.M. Pacific Time on June 4th, 2026, and the polls are now closed. Let's move to the next item on the agenda, the inspector's report. John, please present the results of the voting. The preliminary results of voting are as follows. The nine nominees for election to the board have each been duly elected pursuant to proposal 1, and proposals 2, 3, 4, and 5 have each been approved by the necessary vote identified in the proxy statement that was made available to the stockholders of record. Final voting results will be filed with the minutes of this meeting and will be publicly reported on a current report on Form 8-K within four business days of the end of this meeting. There being no further business properly brought before this meeting, this brings the formal business of the meeting to an end, and I declare the meeting adjourned. Thank you all for attending today's meeting and for your continued support of Assembly Bio. That concludes today's meeting. You may now disconnect.